Oncology pipeline
Our in house programs are in oncology, and we are advancing our lead candidate, CPC634, through a Phase 2 clinical trials in patients with ovarian cancer. We are also progressing CPC879, an innovative oligonucleotide based therapeutic into preclinical studies.
CriPec®-based therapeutics
CriPec®-based therapeutics are new drug modality that is designed and engineered to either passively or specifically target defined cells or tissue in the body. They concentrate a drug payload and extend local exposure at the disease site while minimizing adverse effects on healthy tissues.
CriPec® technology platform
Our proprietary polymeric technology platform, CriPec®, enables the rational design and straightforward manufacturing of custom-made nanomedicines. It can be applied to innovative development candidates and in-market drugs to create novel nanomedicines.
Partnering
We have established several industry partnerships to co-create CriPec®-based therapeutics and assess their applicability in a number of therapeutic areas, including oncology and inflammation.
We are actively seeking partnerships for our proprietary inflammation programs.
Leadership team
We have an experienced management team of entrepreneurial life science executives who bring a powerful combination of leadership, scientific, technical, and clinical expertise.
Watch Informa interview with our CEO/CMO, Dr Axel Mescheder at BIOEurope 2018
Latest News
- Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer 1 August 2019
- Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors 17 May 2019
- Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline 1 November 2018
Events
There are no upcoming events.
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
